Dear colleagues and friends of PATH,

Advances in science and technology are throwing open the doors for new opportunities in health and development in ways that were unimaginable just a few years ago—and upending our assumptions about what were once considered all-but-impossible challenges in global health.

New technologies and investments are expanding access to childhood vaccines, bednets, and other lifesaving interventions, driving steep declines in child mortality. Promising new vaccines and therapies for diarrheal disease, malaria, pneumonia, and other health threats have the potential to increase both life expectancy and quality of life. Mobile technology has reached the most remote corners of the globe, revolutionizing everything from health education to vaccine stock management.

PATH is harnessing the power of these innovations in pursuit of a bold ambition: to redefine the boundaries of what is possible in global health.

Our vision is unwavering—a world where innovation ensures that health is within reach for everyone. Our strategy is dynamic, channeling the tremendous potential of inventive ideas, new resources, groundbreaking collaborations, and cutting-edge discoveries into better health and opportunity for all.

This is innovation in motion.

Driving transformative innovation

From pioneering research to proven, on-the-ground delivery strategies, we accelerate smart ideas and bring lifesaving innovations to scale, connecting evidence-based solutions with the tens of millions of people who have the fewest resources and the greatest need.

We work in more than 70 countries and across nearly 200 projects to drive fresh thinking and new approaches to health technologies and systems, commercial markets, and community engagement. Our “innovation pipeline” of nearly 200 technologies and products accelerates the best ideas from prototype, testing, and validation to pilot introduction and national scale-up.

In these pages, you’ll learn about some of our most compelling accomplishments of 2012 that directly or indirectly touched the lives of more than 118 million people. These milestones include work to advance new vaccine and drug candidates for diarrheal disease, pneumococcal disease, and malaria; prevent HIV infection, cervical cancer, and meningitis A; and expand access to new contraceptive options and safe water.
2012
PATH by the numbers

118 million people
Directly or indirectly benefitting from our work

$313 million
PATH’s 2012 revenue

1,100+
Number of PATH staff

192
Technologies and products in our innovation pipeline

47,000
Health care providers, policymakers, advocates, and others we trained

145
Policies, strategies, and guidelines we worked to influence across 46 countries
Accelerating our impact

PATH draws strength from our heritage of innovation and our proven track record of delivering high-impact tools, technologies, and strategies to transform global health. This includes our pivotal role in the development and delivery of new vaccines and immunization technologies now reaching tens of millions of people. Over the past decade, we have tripled our staff, nearly quadrupled our revenue, and added new capabilities across countries and our five platforms: community-based interventions, devices, diagnostics, drugs, and vaccines.

Now PATH is poised to deliver even greater impact. With new leadership, a sharpened strategy, and targeted investments in key impact areas, we are strengthening our ability to shape the next generation of life-changing advances that will reduce suffering and improve health around the world.

The power of partnership

Nothing PATH does would be possible without our partners and funders, and their essential contributions are highlighted throughout the pages of this report. PATH engages and connects hundreds of diverse partners in the private, public, and nonprofit sectors—from the community to the global levels—to bring innovative ideas to life. Our work is fueled by nearly 1,800 individual donors, foundations, corporations, and institutions—key collaborators in our work to turn bright ideas into breakthrough solutions. We are profoundly grateful for this support.

With our diverse network of partners, PATH is driving innovation that saves lives through far-reaching, long-lasting health solutions for families and communities. With your continuing support and collaboration, we will transform lives and open the doors of opportunity to new generations. Thank you for your commitment to global health.

Steve Davis
President and CEO

Molly Joel Coye, MD, MPH
Chair, Board of Directors
TAKING ON TOP CHILDHOOD KILLERS

In 2012, PATH and our partners:

**Helped 14 countries** introduce rotavirus or pneumococcal vaccines.

**Advanced a vaccine candidate to protect kids** from pneumococcal disease.

**Helped 15,000 Cambodian families** use microloans to buy water filters.
Pneumonia and diarrhea are leading killers of the world’s children, jointly responsible for nearly one-third of all child deaths before five years of age and claiming about 2 million lives annually. PATH tackles both threats with a coordinated strategy that brings together vaccine research and introduction, drug development, and innovative approaches to prevention and treatment, including expanding access to safe drinking water.

Two-in-one approach saves lives

Our trailblazing work in Cambodia on an integrated approach to treat diarrheal disease and pneumonia yielded such convincing results that the country is fast-forwarding to national scale-up, with plans to reach more than 1.6 million children by 2014. In the rural district where we launched a pilot project, cases dropped dramatically after we trained health workers and parents to recognize and treat both health threats. Contributions from individual PATH supporters played a pivotal role in helping us expand this promising approach.

Key partners: Cambodia Ministry of Health; National ARI-CDD Program of the National Maternal and Child Health Centre; UNICEF.
Key funders: UNICEF; individual contributors.

A new drug to beat diarrhea

Our investigational new drug to treat acute secretory diarrhea will proceed into the next round of studies in Bangladesh following the successful completion of two phase 1 clinical studies in the United States. The drug could become the first synthetic drug of its kind to reduce fluid loss, shortening both the duration and severity of symptoms.

Key partner: BioFocus.
Key funder: Bill & Melinda Gates Foundation.

Stopping a deadly threat

The completion of a phase 1 trial of a whole-cell vaccine candidate against the most common cause of severe pneumonia yielded promising results that support continuing clinical development, with additional research planned in Kenya. If successful, this vaccine would provide broad, affordable protection against pneumococcal disease for children in the developing world.

Key partner: Boston Children’s Hospital.
Key funder: Bill & Melinda Gates Foundation.

User-friendly water filters

If everyone had access to safe water and basic sanitation services and hygiene practices, almost 90% of diarrheal deaths could be prevented. To reach families with safe water, PATH developed design guidelines now being used by three Chinese manufacturers selling low-cost household water filters and compatible filter elements. Using creative, market-based strategies that include microfinance loans and commercial partnerships, we have helped bring safe drinking water to hundreds of thousands of low-income consumers in Asia and Africa.

Key partners: Cascade Designs, Inc.; Dukong; Hindustan Unilever; Hydrologic; Ningbo Clean; Pureeasy; VisionFund International.
Key funders: Bill & Melinda Gates Foundation; Laird Norton Family Foundation; individual contributors.

Community access to zinc

Families in Kenya now have over-the-counter access to zinc, which can cut the duration and severity of diarrhea. We are working with provincial and district leaders to ensure this national policy change translates into broader community access and fewer deaths.

Key partner: Kenya’s Division of Child and Adolescent Health.
Key funder: Bill & Melinda Gates Foundation.

Better vaccine stock management

In South Sudan, we tested a cloud-based logistics management system that uses mobile phones to manage vaccine stocks. County stock managers replaced paper-based records with mobile phones to register vaccine stock transactions and submit restocking orders. National and state managers used real-time data to track supply and demand and make ordering and delivery decisions.

We also explored the use of battery-free vaccine refrigerators and hybrid solar-electric systems to maintain the cold chain in rural health outposts, and electric vehicles and specially equipped trucks to streamline vaccine delivery. The projects helped build the evidence base for global vaccine supply innovations, with some now poised for national expansion.

Key partners: Government of the Republic of South Sudan; Logistimo; Vietnam’s National Institute of Hygiene and Epidemiology, National Expanded Programme on Immunization; UNICEF; WHO.
Key funder: Bill & Melinda Gates Foundation.
WHEN FAMILIES ARE HEALTHY, COMMUNITIES ARE, TOO.

2012 milestones
FAMILY HEALTH

In 2012, PATH and our partners:

- Vaccinated 48 million+ people against meningitis A.
- Pledged to deliver up to 12 million doses of an injectable contraceptive for women over four years.
- Reached 200,000 children with nutritionally enhanced Ultra Rice® grains.
Healthy families need tools and medicines to protect women during pregnancy, childbirth, and later in life. They also need childhood vaccines, good nutrition, and contraceptive options for family planning. PATH expands access to cutting-edge solutions that improve the lives of women, babies, and children in developing countries.

Ten nations, 100 million+ protected

More than 100 million people across ten African countries have now received the lifesaving protection of a new vaccine against deadly meningitis A, with 48 million vaccinated in 2012 alone. The MenAfriVac® vaccine was developed through a partnership between PATH and WHO, in collaboration with Serum Institute of India Ltd. The vaccine also became the first in Africa approved for transport and storage outside the traditional cold chain, helping health workers reach people in remote areas.

Key partners: Serum Institute of India Ltd.; WHO; ministries of health in Africa; three dozen global collaborators.

Key funders: Bill & Melinda Gates Foundation; Michael & Susan Dell Foundation; individual contributors.

New contraceptive tool for women

An estimated 215 million women worldwide want to prevent pregnancy but do not use or have access to modern methods of family planning. PATH is paving the way to introduce a new injectable contraceptive adapted for delivery in the Uniject™ injection system developed by PATH. The medication is contained in a prefilled plastic bubble for easy delivery, potentially expanding the bubble for easy delivery, potentially expanding access to modern methods of family planning. PATH helped lead research in Africa and coordinated pilot introduction planning among global and country partners. Individual contributors provided funding to help jump-start pilot introduction.

Key partners: FHI 360; Pfizer, Inc.

Key funders: Bill & Melinda Gates Foundation; The Frankel Foundation; UK Department for International Development; United Nations Population Fund (UNFPA); US Agency for International Development (USAID); The William and Flora Hewlett Foundation; individual contributors.

Combating women’s cancers

With the burden of breast and cervical cancer shifting toward low-income countries, PATH is working to expand access to screening and prevention strategies. In Peru, we developed a community breast health project that screened more than 5,400 women for breast cancer and trained dozens of health providers, fueled by donations from individual contributors providing critical seed money. The project led to a planned national expansion of the model in 2013. In Uganda, the government is gearing up for a national immunization campaign against the primary cause of cervical cancer after a PATH-led project generated evidence on the best ways to introduce the vaccine—a project now informing the work of governments across Africa, Asia, and Latin America to prevent cervical cancer deaths.

Key partners: Government of Uganda; Peru Ministry of Health; Peru National Cancer Institute; Regional Cancer Institute in Trujillo.

Key funders: Bill & Melinda Gates Foundation; Norwegian Cancer Society/ Norwegian Breast Cancer Society; Susan G. Komen for the Cure®; individual contributors.

Better nutrition in every bite

To combat malnutrition, we helped develop innovative distribution models to increase access to rice fortified with vitamins and minerals using PATH’s Ultra Rice® fortification technology. Fortified grains are being integrated into large-scale food assistance programs in Burundi and Cambodia, commercial retail channels in Brazil, and small-scale distribution channels in Vietnam. Gifts from individual donors helped us evaluate the health impact of fortified rice in African children. In India, we helped establish high-quality manufacturing of fortified grains for a World Food Programme pilot project that will reach 98,000 children in 2013.

Key partners: Adorella Aline: Health; Global Alliance for Improved Nutrition; Institut de Recherche pour le Développement; Kansas State University; United Nations World Food Programme; Urban; Usher Agro Ltd.

Key funders: Abbott Fund; Bill & Melinda Gates Foundation; US Department of Agriculture, Foreign Agricultural Service and National Institute of Food and Agriculture; individual contributors.

Speaking out for mothers and children

Essential maternal health medicines can treat and prevent the leading causes of maternal deaths. PATH developed a targeted policy agenda for global and national decision-makers to increase women’s access to these medicines, which cost less than $1 per dose. Advocacy efforts led by PATH also helped safeguard access to childhood vaccines in a global treaty limiting mercury in the environment. We worked with partners to inform and influence key decision-makers, who agreed to exclude vaccines containing the preservative thiomersal from regulation.

Key partners: GAVI Alliance; International Pediatric Association; Management Sciences for Health; Population Action International; UNFPA; UNICEF; USAID.

Key funder: Bill & Melinda Gates Foundation.

MenAfriVac is a registered trademark of Serum Institute of India Ltd. Uniject is a trademark of BD. Ultra Rice is a registered US trademark of Jon Dente International, Inc. careHPV is a trademark of QIAGEN, Inc.
AN AUDACIOUS GOAL: A WORLD FREE OF MALARIA

In 2012, PATH and our partners:

- Trained 1,100+ Zambian health workers in new ways to reduce malaria transmission.
- Advanced a vaccine candidate that cut malaria episodes by 1/3 in a trial with African infants.
- Paved the way to ensure stable supplies of the top malaria drug through production of a key drug ingredient.
Despite remarkable progress in the past decade, malaria still exacts a terrible price from children, families, and communities, killing an estimated 660,000 people each year—most of them young children in sub-Saharan Africa. PATH is mounting an attack on malaria from all sides: expanding the use of lifesaving tools and developing new strategies to create malaria-free communities; accelerating vaccine development; advancing diagnostic technologies; and creating a new, stable supply of the most effective drug treatment. Our ultimate goal is within reach—to eliminate malaria altogether.

Stamping out malaria transmission
PATH is working with national malaria control programs to target the malaria parasite village by village. Our three-step approach combines better data through rapid reporting of malaria cases, testing and treating of entire communities, and improved surveillance systems to track remaining infections. In Zambia, we helped train more than 1,100 workers in this approach in 2012. Ethiopia and Senegal are also laying the groundwork for malaria elimination, with Ethiopia creating malaria elimination learning districts and Senegal using smartphones to report malaria data while conducting community-wide test-and-treat campaigns. Evidence of their progress is driving financial and political commitments to malaria elimination even at a time of fiscal constraint.

Key partners: Governments of Ethiopia, Senegal, and Zambia; Roll Back Malaria Partnership.
Key funders: Bill & Melinda Gates Foundation; individual contributors.

Scaling up diagnosis and treatment
PATH is leading a new project to expand the diagnosis and treatment of malaria and other febrile illnesses in Africa. Through increased use of diagnostic testing, appropriate treatment, and improved laboratory services, MalariaCare aims to cut the burden of malaria by half in a population of 450 million people in Africa.

Key partners: Medical Care Development International; Population Services International; Save the Children.
Key funder: USAID.

New diagnostics for malaria elimination
To support malaria elimination, PATH is identifying and analyzing the unique technical requirements and market needs for diagnostic technologies to detect remaining reservoirs of infection among people who may not show symptoms. Our work will provide countries, donors, and developers with evidence about cost-effective diagnostic tools and tactics as they focus on elimination strategies.

Key funder: Bill & Melinda Gates Foundation.

Lifesaving drugs to protect the most vulnerable
Our new drug development program, which grew out of our affiliation with OneWorld Health, expands our capacity to deliver integrated strategies to reduce the toll of malaria, as well as neglected tropical diseases and diarrheal disease.

A new tool to fight malaria
The high cost and volatile supply of the key ingredient in the most effective malaria treatment can put the drug out of reach for those most at risk. We worked with partners to develop a semisynthetic version of artemisinin to supplement fluctuating botanical supplies and began producing it in 2012. Production is set to expand to up to 60 tons by 2014, providing a more dependable supply of this lifesaving drug for malaria patients.

Key partners: Amyris, Inc.; Gland Pharma; governments of Bangladesh and Nepal; International Centre for Diarrhoeal Disease Research, Bangladesh; Jharkhand State Department of Health; Sanofi; University of California, Berkeley.
Key funders: Bill & Melinda Gates Foundation; UBS Optimus Foundation.

Tackling neglected tropical diseases
Visceral leishmaniasis is a neglected infectious disease endemic in 79 countries that is transmitted through the bite of sand flies, causing swelling of key organs, anemia, and death if left untreated. The antibiotic Paromomycin Intramuscular Injection (PMIM), developed by our drug development program to treat the disease, was registered by the government of Nepal. We also completed a phase 3(b) clinical trial of the therapy in Bangladesh, supporting efforts to register PMIM in that country and contributing to a national elimination strategy for the disease.

We also worked to improve diagnosis and control of helminth (intestinal worm) infection, especially among children in India.

Key partners: Amyris, Inc.; Cipla; governments of Bangladesh and Nepal; International Centre for Diarrhoeal Disease Research, Bangladesh; Jharkhand State Department of Health; Sanofi; University of California, Berkeley.
Key funders: Bill & Melinda Gates Foundation; UBS Optimus Foundation.
Headquartered in Seattle, Washington, United States, PATH works in more than 70 countries in the areas of emerging and epidemic diseases (including HIV/AIDS, malaria, and tuberculosis), health technologies, maternal and child health, reproductive health, and vaccines and immunization. In 2012, we had more than 1,100 staff members and offices in 21 countries.

### Country innovations

#### China
PATH developed a product development partnership with public- and private-sector partners to obtain WHO prequalification on vaccines for global procurement programs.

#### Democratic Republic of the Congo
PATH has reached an estimated 1.4 million people with HIV prevention messages, 430,000 people with counseling and testing, and 80,000 women with services to prevent mother-to-child transmission of HIV, working through nearly 100 local partners.

#### India
We are supporting 13 Asian countries in adopting the Japanese encephalitis vaccine. We also worked to improve maternal and newborn health through proven interventions and community mobilization and built country research capacity by supporting a training program for clinical investigators.

#### Kenya
Through APHIAplus, we helped more than 500,000 people in western Kenya get HIV testing and counseling and more than 53,000
people get treatment. We have reached 6.6 million Kenyan youth with HIV prevention information using digital platforms, a TV series, road shows, and other approaches.

**Myanmar**
PATH launched a project to introduce new approaches to neonatal health, with plans to support other priority health areas in coming years.

**Tanzania**
PATH supported the ministries of health in Tanzania and Zanzibar in developing and implementing an integrated strategy to serve patients with TB and HIV, now used in more than 1,000 health facilities. Health staff identified more than 23,000 TB patients, with 90% tested for HIV and informed of their results.
2012 financial summary (audited)

<table>
<thead>
<tr>
<th>SOURCES OF REVENUE</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foundations</td>
<td>49.5%</td>
</tr>
<tr>
<td>US government</td>
<td>34.6%</td>
</tr>
<tr>
<td>Other governments, nongovernmental organizations (NGOs), multilaterals</td>
<td>11.7%</td>
</tr>
<tr>
<td>Individuals/other</td>
<td>2.2%</td>
</tr>
<tr>
<td>Investments</td>
<td>0.3%</td>
</tr>
<tr>
<td>Corporations</td>
<td>0.7%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>USE OF FUNDS</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emerging and epidemic diseases</td>
<td>39.8%</td>
</tr>
<tr>
<td>Vaccines and immunization</td>
<td>28.8%</td>
</tr>
<tr>
<td>Health technologies</td>
<td>13.2%</td>
</tr>
<tr>
<td>Maternal and child health</td>
<td>10.6%</td>
</tr>
<tr>
<td>Reproductive health</td>
<td>6.0%</td>
</tr>
<tr>
<td>Cross-program initiatives</td>
<td>1.6%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EXPENSE ALLOCATION</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program services</td>
<td>86.4%</td>
</tr>
<tr>
<td>Management and general</td>
<td>12.5%</td>
</tr>
<tr>
<td>Bid and proposal</td>
<td>0.6%</td>
</tr>
<tr>
<td>Fundraising</td>
<td>0.5%</td>
</tr>
</tbody>
</table>

**REVENUE (in thousands)**

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foundations</td>
<td>$154,439</td>
</tr>
<tr>
<td>US government</td>
<td>108,331</td>
</tr>
<tr>
<td>Other governments, nongovernmental organizations (NGOs), multilaterals</td>
<td>36,616</td>
</tr>
<tr>
<td>Individuals/other</td>
<td>7,010</td>
</tr>
<tr>
<td>Investments</td>
<td>4,086</td>
</tr>
<tr>
<td>Corporations</td>
<td>2,337</td>
</tr>
<tr>
<td><strong>TOTAL REVENUE</strong></td>
<td><strong>$312,819</strong></td>
</tr>
</tbody>
</table>

**EXPENSES (in thousands)**

**Program services**

<table>
<thead>
<tr>
<th>Program</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emerging and epidemic diseases</td>
<td>$53,398</td>
</tr>
<tr>
<td>Health technologies</td>
<td>17,755</td>
</tr>
<tr>
<td>Maternal and child health</td>
<td>14,187</td>
</tr>
<tr>
<td>Reproductive health</td>
<td>8,073</td>
</tr>
<tr>
<td>Vaccines and immunization</td>
<td>38,572</td>
</tr>
<tr>
<td>Cross-program initiatives</td>
<td>2,143</td>
</tr>
<tr>
<td><strong>Subtotal programs</strong></td>
<td>134,128</td>
</tr>
<tr>
<td>Program subawards</td>
<td>133,646</td>
</tr>
<tr>
<td><strong>Subtotal program services</strong></td>
<td><strong>$267,774</strong></td>
</tr>
</tbody>
</table>

**Support services**

<table>
<thead>
<tr>
<th>Service</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management and general</td>
<td>$38,599</td>
</tr>
<tr>
<td>Bid and proposal</td>
<td>1,720</td>
</tr>
<tr>
<td>Fundraising</td>
<td>1,503</td>
</tr>
<tr>
<td><strong>Subtotal support services</strong></td>
<td><strong>$41,822</strong></td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td><strong>$309,596</strong></td>
</tr>
</tbody>
</table>

**Assets, liabilities, and net assets**

**ASSETS (in thousands)**

<table>
<thead>
<tr>
<th>Asset</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$40,453</td>
</tr>
<tr>
<td>Invested grant funds</td>
<td>275,355</td>
</tr>
<tr>
<td>Contributions and awards receivable</td>
<td>333,178</td>
</tr>
<tr>
<td>Other</td>
<td>26,429</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$675,415</strong></td>
</tr>
</tbody>
</table>

**LIABILITIES AND NET ASSETS (in thousands)**

<table>
<thead>
<tr>
<th>Liability</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total liabilities</td>
<td>$59,775</td>
</tr>
<tr>
<td><strong>Net assets</strong></td>
<td><strong>$615,640</strong></td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>$590,984</td>
</tr>
<tr>
<td>Unrestricted</td>
<td>21,281</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>3,375</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td><strong>$675,415</strong></td>
</tr>
</tbody>
</table>

Figures are presented in US dollars.

Notes: The above financial summary is an excerpt from PATH’s audited financial statements, which are audited by the firm Clark Nuber P.S. Full copies are available on our website at www.path.org.

PATH is an international, nonprofit, nongovernmental organization. Our mission is to improve the health of people around the world by advancing technologies, strengthening systems, and encouraging healthy behaviors. Contributions to PATH are tax-exempt under US IRS code 501(c)(3).
Executive and program leadership

Board of Directors

PATH’s 2012 board members are public health and business leaders from the countries we serve, Europe, and the United States. The board provides governance and fiduciary oversight, sets policy, and assesses PATH’s overall performance.

Dean Allen  
**TREASURER**  
*United States*  
CEO, McKinstry  
Seattle, WA USA

Phyllis Campbell  
**United States**  
Chairman, Pacific Northwest, JPMorgan Chase & Co.  
Seattle, WA USA

Supamit Chunsuttiwat, MD, MPH  
*Thailand*  
Senior Expert in Disease Control, Ministry of Public Health  
Bangkok, Thailand

Molly Joel Coye, MD, MPH  
**CHAIR**  
*United States*  
Chief Innovation Officer, UCLA Health System, University of California, Los Angeles  
Los Angeles, CA USA

Alex Chika Ezeh, PhD, MSc  
*Nigeria*  
Executive Director, African Population and Health Research Center  
Nairobi, Kenya

George Gotsadze, MD, PhD  
**VICE CHAIR**  
*Republic of Georgia*  
Director, Curatio International Foundation  
Tbilisi, Georgia

Eivor Halkjaer  
**Sweden**  
Former Swedish Ambassador and Former Senior Advisor to the Director General, Swedish International Development Cooperation Agency  
Stockholm, Sweden

Vincent McGee  
**United States**  
Former Senior Advisor, The Atlantic Philanthropies  
New York, NY USA

Woodrow Myers, MD, MBA  
**United States**  
Managing Director, Myers Ventures, LLC  
Indianapolis, IN USA

Kevin Reilly, MBA  
**United States**  
Former President, Wyeth Vaccines and Nutrition  
Rosemont, PA USA

Jay Satia, PhD  
**SECRETARY**  
*India*  
Senior Advisor, Public Health Foundation of India, and Director, Indian Institute of Public Health  
Gandhinagar, Gujarat, India

continued on next page
For the ninth year in a row, PATH has earned the highest possible rating of four stars from Charity Navigator, the leading independent charity evaluator. This is a distinction achieved by just 1% of rated charities, and it recognizes our commitment to careful financial management, as well as our organizational accountability and transparency.

Charity Navigator also included PATH on its list of “10 of the Best Charities Everyone’s Heard Of”—defined as large, complex organizations with budgets exceeding $100 million, at least $65 million in net assets, and exceptional financial management.

“Charitable givers should feel confident that these national institutions put their donations to good use,” according to Charity Navigator.
In 2012, more than 140 foundations, governments, international agencies, nongovernmental and health organizations, universities, and corporations supported our work around the world. In addition, more than 1,600 individual donors and family foundations provided crucial financial support. We are grateful to all of our supporters. This list includes institutions and individuals providing $10,000 or more in funding to PATH through grants, donations, and in-kind contributions in 2012. For a complete list of our supporters, please visit www.path.org.

Foundations
Anonymous (2)
Abbott Fund
The Atlantic Philanthropies
Bill & Melinda Gates Foundation
Conrad N. Hilton Foundation
Dean & Vicki Allen/McKinstry Charitable Foundation
Elizabeth Glaser Pediatric AIDS Foundation
ExxonMobil Foundation
Foundation for Development of Ukraine
Foundation for Innovative New Diagnostics
The Frankel Foundation
Fred H. Bixby Foundation
Global Health Technologies Competitiveness Fund
Horace W. Goldsmith Foundation
The John D. and Catherine T. MacArthur Foundation
Keith & Mary Kay McCaw Family Foundation
Laird Norton Family Foundation
MAC AIDS Fund
Martin-Fabert Foundation
Medtronic Foundation
Michael & Susan Dell Foundation
M.J. Murdoch Charitable Trust
Mocassin Lake Foundation
The Moriah Fund
The Norcliffe Foundation
Open Society Foundations
The Overbrook Foundation
The Rockefeller Foundation
Seattle International Foundation
Sheng-Yen Lu Foundation
Shickman Family Foundation
Silver Family Foundation
Skoll Foundation
Starbucks Foundation
Stavros Niarchos Foundation
Susan G. Komen for the Cure
The Trustees of Columbia University
UBS Optimus Foundation
Vanguard Charitable Endowment Program
Vitol Foundation
Wallace Alexander Gerbode Foundation
The William and Flora Hewlett Foundation

Governments and international agencies
Canadian International Development Agency
Centers for Disease Control and Prevention
Defense Threat Reduction Agency
Department for International Development, United Kingdom
GAVI Alliance
Global Alliance for Improved Nutrition
Ministry of Foreign Affairs, the Netherlands
Ministry of Foreign Affairs, Norway
Ministry of Public Health, Thailand
National Health Security Office, Thailand
National Institutes of Health
National Lung Hospital, Vietnam

Nongovernmental and health organizations and universities
Abt Associates
Agros International
Cancer Research UK
Chemonics International
dance4life International
Drugs for Neglected Diseases initiative
FHI 360
Georgia Institute of Technology
Global Alliance for Livestock Veterinary Medicines
Global Health Nexus, Seattle
Gynuity Health Projects
ICF International

continued on next page
Instituto de Salud Global de Barcelona
International Clinical Epidemiology Network
International Development Enterprises
International Potato Center/Centro Internacional de la Papa
IntraHealth International, Inc.
Jhpiego
John Snow, Inc.
Keck Graduate Institute of Applied Life Sciences
London School of Hygiene & Tropical Medicine
Management Sciences for Health
NicaSalud Network Federation
Norwegian Cancer Society
Pathfinder International
PCI
Plan International
Puntos de Encuentro
The Research Council of Norway
Roll Back Malaria Partnership
RTI International
Save the Children
Seattle BioMed
Seattle Children’s
Task Force for Global Health
Tulane University
Universal Access to Female Condoms
University of Bristol
University of California, Davis
University of Georgia
University of Maryland
University of Washington
University Research Co., LLC
The White Ribbon Alliance for Safe Motherhood

Bharat Biotech
BHP Billiton Sustainable Communities Trust
CH2M HILL
Chevron Corporation
Claremont BioSolutions
Crucell
DSM Nutritional Products
Eulysis Ltd.
GlaxoSmithKline
The Global Good Fund I, LLC
Google Inc.
Hewlett-Packard Development Company, LP
JPMorgan Chase
Laerdal Global Health A/S
Masimo Corporation
MasterCard Worldwide
MBio Diagnostics, Inc.
Merck & Co., Inc.
Microsoft Corporation
Sanergy
Sanofi Pasteur India
SID Technologies, LLC
Zyomyx, Inc.

Howard and Nancy Johnson
Patricia Keegan and Tom Lennon
Emily and Michael Kohler
Rich Lane and Tracey Yonick
Vincent McGee
W.A. Myers, Jr.
Kathy O’Driscoll
Open Road Alliance
Dana I. Pigott
John and Megan Pigott
Ann Ramsay-Jenkins
Benjamin E. Segal and Jacqueline Mahal
Patty Stonesifer and Michael Kinsley
Scott C. and Colleen Stromatt
Kathy Surace-Smith and Brad Smith
Sarah Temple and Peggy Johnston
Dilip Wagle and Darshana Shanbhag
Martin and Geana Wolfram
David Wu and Richard Hansen
Melissa Waggener Zorkin

We do our utmost to ensure that our supporters’ names are represented accurately and according to their requests. If your name is not correctly listed, please contact us at 206-302-4564 or development@path.org to update the information.

Corporations
Anonymous
Arbor Vita Corporation
Aristides Capital, LLC
Beijing Tiantan Biological Products Co., Ltd.

Individuals
Anonymous
Dean & Vicki Allen/McKinstry Charitable Foundation
Lisa and Michael Anderson
Phyllis and Bill Campbell
Brad and Judy Chase
Ty Cramer and Steve Romein
Susanna L. Cunningham
Leslie Danoff and Lawrence Robbins
Steve Davis and Bob Evans
Christopher J. Elias and Therese Caouette
Stephanie Evans
Judith Fong
Andrew Frey
Earl and Mary Kay Gardner
Matt Griffin and Evelyne Rozner